Netherlands· NL-9d9a9227346b

Rivaroxaban CF 15 mg, filmomhulde tabletten

A rivaroxaban product containing rivaroxaban, registered in Netherlands by Centrafarm B.V.. The same ATC class is registered in 15 of our 19 countries.

ATC B01AF01

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about rivaroxabanAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Rivaroxaban is registered in 15 of 19 countries.

Countries holding a registration under ATC B01AF01 (rivaroxaban), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
9 of them publish a price we can compare per daily dose

Search rivaroxaban products by name

Rivaroxaban · ATC B01AF01

15 / 19 countries

Belgiumprice
Canada
Czechiaprice
Denmark
Finlandprice
Germany
Icelandprice
Ireland
Italyprice
Netherlands
Norwayprice
Polandprice
Switzerlandprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of rivaroxaban costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.67 in France to $5.20 in United States — a ×7.7 gap.

4 markets with a comparable price for this class
Public list prices, converted to USD at the rate date shown
US figures are pharmacy acquisition cost (CMS NADAC), not retail

Open the full comparison — free account Drug prices for market access

Rivaroxaban · price per daily dose (20 mg)

USD · FX 28 Sept 2026

US United States$5.20 (acquisition cost)
CH Switzerland$2.66
IT Italy$1.08
FR France$0.67

Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: RIVAROXABAN
Manufacturer: Centrafarm B.V.
Country: Netherlands (NL)
ATC code: B01AF01
ATC class: Rivaroxaban
Defined daily dose: 20 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
128250

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

391 interactions on record for rivaroxaban.

Graded by severity as the source publishes them — 134 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check rivaroxaban against other medicines How interaction checks work

Rivaroxaban · interactions on record

391 records

134 severe
213 moderate
2 minor

Most severe, free to view

LonafarnibA16AX20severe
DicoumarolB01AA01severe
WarfarinB01AA03severe
HeparinB01AB01severe

42 more interactions with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Rivaroxaban in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All rivaroxaban products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

Austria · Rivahib, Rivaroksaban Grindeks
Belgium · Rivaroxaban, Rivaroxaban  Eg
Bulgaria · Xaboplax Sandoz Pharmaceuticals D.D, Виатрикс
Cyprus · Enkia, Naxat
Czechia · Axaltra, Bevimlar
Germany · Elmardya, Rivadia
Denmark · Blomensy, Dovequa
Estonia · Enkia, Kardatuxan
Spain · Blomensy, Elmardya
Finland · Blomensy, Dovequa
France · Elmardya, Rivaroxaban Almus
United Kingdom (Northern Ireland) · Rivaroxaban, Rivaroxaban Abdi
Greece · Blomensy, Cinstel
Croatia · Aban, Bevimlar
Hungary · Dovequa, Evoxyr
Ireland · Rivaroxaban Ascend, Rivaroxaban Azure
Iceland · Agublon, Barsovi
Italy · Ellebax, Indifaxa
Liechtenstein · Rivaroxaban Accord, Rivaroxaban Viatris
Lithuania · Enkia, Kardatuxan
Luxembourg · Rivaroxaban Eg, Rivaroxaban Eg (Eurogenerics) Nv
Latvia · Kardatuxan, Mibrex
Malta · Enkia, Naxat
Norway · Dovequa, Rivaroxaban Accord
Poland · Axaltra, Bevimlar
Portugal · Closderive, Enkia
Romania · Closderive, Enkia
Sweden · Bevimlar, Blomensy
Slovenia · Dovequa, Ribas
Slovakia · Assubex, Bevimlar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/b5917a8e-7a12-4734-a135-cc7c94290ccf
GET /v1/drugs/b5917a8e-7a12-4734-a135-cc7c94290ccf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h128250_smpc.pdf",
  "strength": null,
  "atc_label": "Rivaroxaban",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg128250",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "HYPROMELLOSE (E 464)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 4000",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL, GEPREGELATINEERD",
    "NATRIUMLAURILSULFAAT",
    "POVIDON K 30 (E 1201)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "RIVAROXABAN"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h128250.pdf",
  "authorised_at": "2022/10/21",
  "procedure_number": "SE/H/2153/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "128250",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about rivaroxaban.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console